Literature DB >> 26224871

Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity.

Ningyan Zhang1, Hui Deng2, Xuejun Fan2, Anneliese Gonzalez3, Songlin Zhang4, Randall J Brezski5, Byung-Kwon Choi2, Michael Rycyzyn5, William Strohl5, Robert Jordan6, Zhiqiang An1.   

Abstract

PURPOSE: Studies have demonstrated that cancer-associated matrix metalloproteinases (MMP) can generate single peptide bond cleavages in the hinge region of immunoglobulin G1 (IgG1). This study investigated the cleavage of endogenous IgGs by MMPs in the tumor microenvironment and the consequences of the IgG hinge cleavage for humoral immunity. EXPERIMENTAL
DESIGN: We investigated the occurrence of single peptide bond cleaved IgGs (scIgG) in tumor tissues and plasma samples collected from a cohort of breast cancer patients (n = 60). Samples from healthy people (n = 20) were used as the control. Antibody hinge cleavage was detected by multiple assays, including IHC, ELISA, and flow cytometry. A correlation analysis was conducted between scIgG levels and patient clinical parameters.
RESULTS: Levels of scIgGs in tumors were significantly higher than in normal tissues. In addition, scIgG levels in tumors were enriched compared with that in the plasma of the same patients. The appearance of scIgGs in tumor tissues was associated with altered host IgG content and decreased IgG1. Increased tumor scIgGs were found to be positively correlated with adverse clinical factors, such as elevated tumor-associated macrophages, increased expression of MMP9 and other MMPs, and local metastasis to axillary lymph nodes.
CONCLUSIONS: The study contributes to mounting evidence for the presence of hinge-cleaved antibodies with reduced Fc immune effector function in the tumor microenvironment. The results highlight a link between tumor scIgGs and poor patient outcomes, and reveal a component of compromised humoral immunity within tumors that could point to new immunotherapeutic strategies to rescue host immunity. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26224871     DOI: 10.1158/1078-0432.CCR-15-1057

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

1.  Human endotrophin as a driver of malignant tumor growth.

Authors:  Dawei Bu; Clair Crewe; Christine M Kusminski; Ruth Gordillo; Alexandra L Ghaben; Min Kim; Jiyoung Park; Hui Deng; Wei Xiong; Xiao-Zheng Liu; Per Eystein Lønning; Nils Halberg; Adan Rios; Yujun Chang; Anneliese Gonzalez; Ningyan Zhang; Zhiqiang An; Philipp E Scherer
Journal:  JCI Insight       Date:  2019-03-21

2.  Tumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function.

Authors:  Ningyan Zhang; Robert E Jordan; Zhiqiang An
Journal:  Oncoimmunology       Date:  2015-12-29       Impact factor: 8.110

3.  Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.

Authors:  Hao-Ching Hsiao; Xuejun Fan; Robert E Jordan; Ningyan Zhang; Zhiqiang An
Journal:  Breast Cancer Res       Date:  2018-06-01       Impact factor: 6.466

Review 4.  Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.

Authors:  Yara Al Ojaimi; Timothée Blin; Juliette Lamamy; Matthieu Gracia; Aubin Pitiot; Caroline Denevault-Sabourin; Nicolas Joubert; Jean-Pierre Pouget; Valérie Gouilleux-Gruart; Nathalie Heuzé-Vourc'h; Débora Lanznaster; Sophie Poty; Thomas Sécher
Journal:  Pharmacol Ther       Date:  2021-10-20       Impact factor: 13.400

5.  Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions.

Authors:  Xuejun Fan; Zihao Yuan; Yueshui Zhao; Wei Xiong; Hao-Ching Hsiao; Rahmawati Pare; Jianmin Ding; Ahmad Almosa; Kai Sun; Songlin Zhang; Robert E Jordan; Cheok Song Lee; Zhiqiang An; Ningyan Zhang
Journal:  Commun Biol       Date:  2022-09-14

Review 6.  Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers.

Authors:  Yasmine Lounici; Olivia Le Saux; Gabriel Chemin; Pauline Wajda; Sarah Barrin; Justine Berthet; Christophe Caux; Bertrand Dubois
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

7.  Grp94 in complexes with IgG is a soluble diagnostic marker of gastrointestinal tumors and displays immune-stimulating activity on peripheral blood immune cells.

Authors:  Elisa Tramentozzi; Erlis Ruli; Imerio Angriman; Romeo Bardini; Michela Campora; Vincenza Guzzardo; Rita Zamarchi; Elisabetta Rossi; Massimo Rugge; Paola Finotti
Journal:  Oncotarget       Date:  2016-11-08

Review 8.  Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy.

Authors:  Robert E Jordan; Xuejun Fan; Georgina Salazar; Ningyan Zhang; Zhiqiang An
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

9.  The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.

Authors:  Quentin Deveuve; Laurie Lajoie; Benjamin Barrault; Gilles Thibault
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

10.  Recurrence Risk of Liver Cancer Post-hepatectomy Using Machine Learning and Study of Correlation With Immune Infiltration.

Authors:  Xiaowen Qian; Huilin Zheng; Ke Xue; Zheng Chen; Zhenhua Hu; Lei Zhang; Jian Wan
Journal:  Front Genet       Date:  2021-12-08       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.